WO2018230931A3 - Composition for preventing or treating metabolic diseases - Google Patents
Composition for preventing or treating metabolic diseases Download PDFInfo
- Publication number
- WO2018230931A3 WO2018230931A3 PCT/KR2018/006641 KR2018006641W WO2018230931A3 WO 2018230931 A3 WO2018230931 A3 WO 2018230931A3 KR 2018006641 W KR2018006641 W KR 2018006641W WO 2018230931 A3 WO2018230931 A3 WO 2018230931A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preventing
- metabolic diseases
- treating metabolic
- composition
- fat
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 abstract 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000004132 lipogenesis Effects 0.000 abstract 1
- 230000003520 lipogenic effect Effects 0.000 abstract 1
- 210000005228 liver tissue Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Abstract
The present invention relates to a composition for preventing or treating metabolic diseases and, more particularly, to a pharmaceutical composition and a food composition for preventing, alleviating, or treating metabolic diseases, comprising an extract of Gentianae Macrophyllae Radix as an active ingredient. The method of the present invention promotes AMPK activity; inhibits fat accumulation, fat granulation, lipogenesis transcription factor SREBP-1c activity, and lipogenic enzyme expression; and reduces body weight, fat tissue and liver tissue weight, blood glucose, triglycerides, and cholesterol content, and thus may be effectively used for preventing or treating metabolic diseases such as obesity, diabetes, hypertriglyceridemia, hypercholesterolemia, and the like.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0074193 | 2017-06-13 | ||
| KR1020170074193A KR101819221B1 (en) | 2017-06-13 | 2017-06-13 | Composition for preventing or treating metabolic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2018230931A2 WO2018230931A2 (en) | 2018-12-20 |
| WO2018230931A3 true WO2018230931A3 (en) | 2019-02-07 |
Family
ID=61028727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2018/006641 WO2018230931A2 (en) | 2017-06-13 | 2018-06-12 | Composition for preventing or treating metabolic diseases |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101819221B1 (en) |
| WO (1) | WO2018230931A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101819221B1 (en) * | 2017-06-13 | 2018-01-18 | 중앙대학교 산학협력단 | Composition for preventing or treating metabolic disease |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070033133A (en) * | 2005-09-21 | 2007-03-26 | 에스케이케미칼주식회사 | A composition for external preparation for the protection and the treatment of atopic dermatitis |
| KR100720671B1 (en) * | 2006-02-23 | 2007-05-21 | 경희대학교 산학협력단 | The composition comprising extracts of gentiana scabra, citrus unshiu marcor and coptis chinensis for treatment of type iv allergy and an inflammation |
| KR20140147482A (en) * | 2013-06-20 | 2014-12-30 | 경희대학교 산학협력단 | Composition for preventing or treating prediabetes or diabetes comrising fractionation of Gentiana scabra extracts |
| CN105012769A (en) * | 2015-08-21 | 2015-11-04 | 陈爱红 | Traditional Chinese medicine composition for treating diabetes and preparation method of traditional Chinese medicine composition |
| KR101819221B1 (en) * | 2017-06-13 | 2018-01-18 | 중앙대학교 산학협력단 | Composition for preventing or treating metabolic disease |
-
2017
- 2017-06-13 KR KR1020170074193A patent/KR101819221B1/en active IP Right Grant
-
2018
- 2018-06-12 WO PCT/KR2018/006641 patent/WO2018230931A2/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070033133A (en) * | 2005-09-21 | 2007-03-26 | 에스케이케미칼주식회사 | A composition for external preparation for the protection and the treatment of atopic dermatitis |
| KR100720671B1 (en) * | 2006-02-23 | 2007-05-21 | 경희대학교 산학협력단 | The composition comprising extracts of gentiana scabra, citrus unshiu marcor and coptis chinensis for treatment of type iv allergy and an inflammation |
| KR20140147482A (en) * | 2013-06-20 | 2014-12-30 | 경희대학교 산학협력단 | Composition for preventing or treating prediabetes or diabetes comrising fractionation of Gentiana scabra extracts |
| CN105012769A (en) * | 2015-08-21 | 2015-11-04 | 陈爱红 | Traditional Chinese medicine composition for treating diabetes and preparation method of traditional Chinese medicine composition |
| KR101819221B1 (en) * | 2017-06-13 | 2018-01-18 | 중앙대학교 산학협력단 | Composition for preventing or treating metabolic disease |
Non-Patent Citations (1)
| Title |
|---|
| KIM, HAN-SOO ET AL.: "Effects of Gentiana Scabra Bunge Var.buergeri Max Extract on Lipid Metabolism of Serum in Dietary Hyperlipidemic Rats", JOURNAL OF LIFE SCIENCE, vol. 8, no. 5, 1998, pages 532 - 536, XP053021468 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018230931A2 (en) | 2018-12-20 |
| KR101819221B1 (en) | 2018-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rangboo et al. | The effect of artichoke leaf extract on alanine aminotransferase and aspartate aminotransferase in the patients with nonalcoholic steatohepatitis | |
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| WO2006127007A3 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| WO2011127304A3 (en) | Methods of treating an overweight subject | |
| BRPI0819690B8 (en) | use of a composition comprising cysteamine or cystamine, or a pharmaceutically acceptable salt thereof | |
| MX2019014410A (en) | Methods of treating fabry patients having renal impairment. | |
| SG11201807500RA (en) | Agent for increasing intestinal butyric acid and proliferation agent for butyric acid-producing bacteria | |
| WO2010030054A3 (en) | Uses of sesquiterpene derivatives | |
| WO2018093238A3 (en) | Composition comprising as active ingredient strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity | |
| WO2012033792A3 (en) | Treatment of diseases | |
| WO2008149802A1 (en) | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient | |
| ATE522224T1 (en) | MEDICAL HERBAL EXTRACT WITH ANTI-OBESITY EFFECT | |
| CN104273540A (en) | Antrodia camphorata composition | |
| WO2018093237A3 (en) | Composition comprising formic acid or pharmaceutically acceptable salt thereof as active ingredient for preventing or treating obesity or metabolic syndromes caused by obesity | |
| WO2018230931A3 (en) | Composition for preventing or treating metabolic diseases | |
| WO2016190566A3 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
| WO2011052935A3 (en) | Composition for lowering blood sugar, comprising extract of smilax chine l., momordica charantia and cordyceps militaris as active ingredient | |
| WO2009084875A3 (en) | Composition for preventing and treating metabolic diseases comprising the extract of lysimachiae foenum-graeci herba | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| WO2011090265A3 (en) | Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome | |
| CA3156680A1 (en) | Methods and compositions for treatment of rett syndrome | |
| WO2009035253A3 (en) | Novel use of scoparone | |
| NZ708511A (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
| WO2012091425A3 (en) | Composition containing a 4-hydroxytamoxifen analog or the pharmaceutically acceptable salts thereof as an active ingredient for preventing or treating diseases associated with metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18817447 Country of ref document: EP Kind code of ref document: A2 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18817447 Country of ref document: EP Kind code of ref document: A2 |